LASAGNA, ANGIOLETTA
 Distribuzione geografica
Continente #
NA - Nord America 376
EU - Europa 230
AS - Asia 40
AF - Africa 2
OC - Oceania 1
Totale 649
Nazione #
US - Stati Uniti d'America 376
IE - Irlanda 97
IT - Italia 70
FI - Finlandia 36
CN - Cina 31
DE - Germania 15
AT - Austria 5
IN - India 3
BE - Belgio 2
HK - Hong Kong 2
MA - Marocco 2
TR - Turchia 2
AU - Australia 1
HR - Croazia 1
IL - Israele 1
LU - Lussemburgo 1
NL - Olanda 1
RO - Romania 1
SG - Singapore 1
UA - Ucraina 1
Totale 649
Città #
Chandler 97
Dublin 93
New York 48
Ashburn 41
Helsinki 36
Shanghai 19
Seattle 18
Princeton 14
Lawrence 13
Medford 12
Milan 12
Beijing 9
Rome 8
Wilmington 6
Los Angeles 5
Vienna 5
Pavia 4
Bergamo 3
Guangzhou 3
Reggio Emilia 3
Washington 3
Alghero 2
Ann Arbor 2
Bolu 2
Jette 2
Livorno 2
Muggiò 2
Norwalk 2
Ospitaletto 2
Pune 2
Serrone 2
Tangier 2
Amsterdam 1
Borca 1
Brugherio 1
Central 1
Clarks Summit 1
Crotone 1
Frankfurt am Main 1
Gunzenhausen 1
Gurgaon 1
Haifa 1
Latina 1
Lodi 1
Luxembourg 1
Melbourne 1
Nagold 1
Redwood City 1
Rovello Porro 1
San Diego 1
San Francisco 1
Woodbridge 1
Zagreb 1
Totale 495
Nome #
Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? 41
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 41
The institution of a Multi-disciplinary Italian Breast Unit: Reflections of the first psychosocial research study results on distress and quality of life 36
How to use prophylactic G-CSF in the time of COVID-19 35
Reply to Y. Ergun et al 35
Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center 34
Vickers micro-hardness of new restorative CAD/CAM dental materials: Evaluation and comparison after exposure to acidic drink 33
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors 33
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research 31
G-CSF and G-CSF-related vasculitis: A systematic review of the literature and intriguing future research perspectives 31
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 31
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 30
Torque teno virus and cancers: current knowledge 24
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 24
Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended? 23
Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA 17
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 16
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 15
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study 14
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 14
Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir 14
The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study 14
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 13
COVID-19 and breast cancer: May the microbiome be the issue? 13
The 'hit-and-run' strategy and viral carcinogenesis 12
Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study 12
Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience 11
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment 11
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 10
Infectious complications and immunotherapy: old pitfalls and new horizons 9
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) 7
Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma 6
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 3
Totale 693
Categoria #
all - tutte 3.673
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.673


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 1 0 0 2 0 0 0 6 0
2020/20216 0 0 0 0 0 1 3 1 0 0 0 1
2021/202284 6 0 1 0 4 1 10 5 2 11 7 37
2022/2023285 22 29 4 26 21 13 0 10 114 2 40 4
2023/2024309 41 51 14 22 29 85 24 31 0 11 1 0
Totale 693